ALB and hepatocellular carcinoma: Moreover, in a phase II trial of 21 patients with unresectable HCC treated with combined RT and camrelizumab (an anti-PD1), grade 1–2 adverse events comprised increased AST in 11 patients (52.4%), increased ALT in 10 (47.6%), increased blood bilirubin in 4 (19.1%), and decreased albumin in 11 (52.4%) [13].